Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05158621 · ClinicalTrials.gov registry record
A Screening Study Targeting Tumor-specific Antigens
A clinical trial, sponsored by Gritstone bio.
- Completed
- Registry status
- 22
- Enrollment target
NCT05158621: Completed study, sponsored by Gritstone bio.
NCT05158621 is a clinical trial that has completed, run by Gritstone bio. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05158621 has completed, sponsored by Gritstone bio.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to identify patients who may be eligible to participate in a separate Phase 2/3 treatment study evaluating an individualized neoantigen vaccine GRANITE for first line (1L) maintenance treatment of metastatic, microsatellite-sable colorectal cancer (MSS-CRC) sponsored by Gritstone bio. This may include the manufacturing of an individualized vaccine, which involves neoantigen prediction and generating a vaccine targeting neoantigens.
Primary Outcome
To identify patients with a defined tumor-specific profile (or tumor-specific characteristics, proteins, mutations) for potential inclusion in a separate clinical study that involves investigational study treatment.
Interventions
- PROCEDURE blood collection for research (next generation sequencing [NGS])
- PROCEDURE blood collection for research (HLA typing)
- PROCEDURE blood collection for research (circulating tumor DNA [ctDNA])
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2022-08-15 |
What the finished NCT05158621 record still lists
NCT05158621 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which blood collection for research (next generation sequencing [NGS]) is the first listed.
NCT05158621 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05158621 about?
NCT05158621 is a clinical study titled "A Screening Study Targeting Tumor-specific Antigens". The purpose of this study is to identify patients who may be eligible to participate in a separate Phase 2/3 treatment study evaluating an individualized neoantigen vaccine GRANITE for first line (1L) maintenance treatment of metastatic, microsatellite-sable colorectal cancer (MSS-CRC) sponsored by ...
What is the current status of trial NCT05158621?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2021-12-14. Estimated completion is 2022-08-15.
What interventions are being tested in trial NCT05158621?
The interventions under investigation include: blood collection for research (next generation sequencing [NGS]) (PROCEDURE), blood collection for research (HLA typing) (PROCEDURE), blood collection for research (circulating tumor DNA [ctDNA]) (PROCEDURE).
Who is sponsoring clinical trial NCT05158621?
This trial is sponsored by Gritstone bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI